Risperidone ( DrugBank: Risperidone )

5 diseases

8. ハンチントン病

臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04201834 (ClinicalTrials.gov)	August 13, 2020	13/12/2019	Risperidone for the Treatment of Huntington's Disease Involuntary Movements	Risperidone for the Treatment of Huntington's Disease Chorea	Huntington Disease;Chorea	Drug: Risperidone;Device: BioStamp nPoint device	University of Rochester	NULL	Suspended	18 Years	65 Years	All	12	Phase 2	United States
2	NCT04071639 (ClinicalTrials.gov)	March 12, 2020	26/8/2019	Symptomatic Therapy for Patients With Huntington's Disease	Non-randomized Control Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease Patients	Huntington Disease	Drug: Haloperidol 2Mg Tab;Drug: Risperidone 1Mg Tab;Drug: Zoloft 50Mg Tablet;Drug: Idebenone;Drug: Deutetrabenazine Oral Tablet [Austedo]	Second Affiliated Hospital, School of Medicine, Zhejiang University	NULL	Recruiting	N/A	N/A	All	60	Phase 1	China

臨床試験数 : 44 / 薬物数 : 61 - (DrugBank : 23) / 標的遺伝子数 : 57 - 標的パスウェイ数 : 83

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00261508 (ClinicalTrials.gov)	August 1999	2/12/2005	A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD)	Efficacy And Safety Of Risperidone In The Treatment Of Children With Autistic Disorder And Other Pervasive Developmental Disorders: A Canadian, Multicenter, Double-Blind, Placebo-Controlled Study	DCild Development Disorders, Pervasive;Autistic Disorder;Developmental Disabilities;Asperger Syndrome;Rett Syndrome	Drug: risperidone	Janssen-Ortho Inc., Canada	NULL	Completed	5 Years	12 Years	Both	80	Phase 3	NULL

臨床試験数 : 5 / 薬物数 : 14 - (DrugBank : 7) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 32

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00768820 (ClinicalTrials.gov)	May 2001	7/10/2008	The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome	The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors	Velocardiofacial Syndrome;Williams Syndrome;Fragile X Syndrome	Drug: methylphenidate, fluoxetin, risperidone	The Chaim Sheba Medical Center	NULL	Recruiting	N/A	N/A	All	400	Phase 4	Israel

臨床試験数 : 4 / 薬物数 : 9 - (DrugBank : 2) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 11

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00723580 (ClinicalTrials.gov)	May 2008	24/7/2008	Actigraphic Analysis of Treatment Response	Actigraphic Analysis of Treatment Response in a Six Year Old Girl With Kabuki Syndrome	Sleep Disorders, Circadian Rhythm;Insomnia;Psychomotor Agitation	Drug: risperidone	Child Psychopharmacology Institute	NULL	Completed	2 Years	10 Years	Female	1	N/A	United States

臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00768820 (ClinicalTrials.gov)	May 2001	7/10/2008	The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome	The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors	Velocardiofacial Syndrome;Williams Syndrome;Fragile X Syndrome	Drug: methylphenidate, fluoxetin, risperidone	The Chaim Sheba Medical Center	NULL	Recruiting	N/A	N/A	All	400	Phase 4	Israel